Zobrazeno 1 - 10
of 92
pro vyhledávání: ''
Autor:
Pierre Thirion, Paul J. Kelly, Helen Matthews, Anne-Marie Baird, Raymond S. McDermott, John Feeney, Olwyn Deignan, John Greene, Ausra Teiserskiene, John McCaffrey, Imelda Parker, Stephen P. Finn, Sylva Helanova, Marvin Lim
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Radium-223 and enzalutamide are approved agents for patients with metastatic castration-resistant prostate cancer (mCRPC). Combining radium-223 and enzalutamide to improve outcomes is of clinical interest due to their differing modes of a
Autor:
Markus Raderer, Peter R. Mazal, Elisabeth Kretschmer-Chott, Barbara Kiesewetter, Christian Scheuba, Alexander Haug, Philipp Riss
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Adrenocortical carcinoma (ACC) is a rare malignancy characterized by aggressive biology and potential endocrine activity. Surgery can offer cure for localized disease but more than half of patients relapse and primary unresectable or metastasized dis
Autor:
Pi-Hung Tung, Cheng-Ta Yang, Fu-Tsai Chung, Chin-Chou Wang, Chi-Hsien Huang, Yike Guo, Allen Chung-Cheng Huang, Yueh-Fu Fang, Chih-Hsi Scott Kuo, Jia-Shiuan Ju, Tzu-Hsuan Chiu, Chien-Ying Liu
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: There are limited comparisons of first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor ( EGFR) mutations. Meth
Autor:
Jeremias Götschke, Christiane Bickert, Kathrin Kahnert, Zulfiya Syunyaeva, Jürgen Behr, Amanda Tufman, Diego Kauffmann-Guerrero
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Osimertinib is a third generation Tyrosine Kinase Inhibitor (TKI) that has become an effective first-line treatment option for metastatic non-small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations. It demonstrated e
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Small cell lung cancer (SCLC) is a highly proliferative, aggressive form of lung cancer that carries a poor prognosis. Recent approvals with new therapeutic options represent the first in more than a decade for SCLC. Lurbinectedin, a newly approved s
Autor:
Yang Zhao, Huan-Wei Chen, Minshan Chen, Li Xu, Yaojun Zhang, Run-Bin Liang, Ming Shi, Rong Ping Guo, Zhi-Cheng Lai, Qi-Jiong Li, Min-Ke He, Yu-Jie Xu, Wei Wei, Yuan-Min Zhou
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background:Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and immune checkpoint inhibitors showed promising results for adv
Autor:
Kohei Shitara, Daisuke Kotani
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Trastuzumab deruxtecan (T-DXd) is a novel anti-human epidermal growth factor receptor 2 (HER2) antibody–drug conjugate composed of a monoclonal anti-HER2 antibody and a topoisomerase I inhibitor, DX-8951 derivative (an exatecan derivative). T-DXd s
Autor:
Laura Matteucci, Flavia Pagan, Giulia Bartolini, Alessandro Passardi, Silvia Ruscelli, Manlio Monti, Bernadette Vertogen, Emanuela Scarpi, Giovanni Luca Frassineti, Giulia Rovesti, Martina Valgiusti, Andrea Casadei Gardini
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Europe PubMed Central
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Europe PubMed Central
Aims: We created a new index (Multi Inflammatory Index, MII) composed of an inflammatory index [neutrophil-to lymphocyte-ratio (NLR): MII-1; platelet-to-lymphocyte ratio (PLR): MII-2; or systemic immune-inflammation index (SII): MII-3] and C-reactive
Autor:
Luca Bottiglieri, Maria Saveria Rotundo, Maria Giulia Zampino, Wanda Petz, Veronica Dell’Acqua, Cristina Trovato, Uberto Fumagalli Romario, Emilio Bertani, Vincenzo Bagnardi, Alessia Surgo, Paola Simona Ravenda, Nicola Fazio, Giulia Peveri
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background and Aims: The standard treatment of non-metastatic anal squamous cell carcinoma (ASCC) consists of chemotherapy with mitomycin (MMC) plus 5-fluorouracil (5FU) for 1–2 cycles concomitant with pelvic radiotherapy. Subsequent studies introd
Autor:
Serena Giacomazzi, Camilla Zecchetto, Vita Fedele, Cristiana Piazzola, M. Pavarana, Raffaela Santoro, Valeria Merz, Francesca Simionato, Giovanni de Manzoni, Alessandro Cavaliere, Simona Casalino, Martina Pasquato, Simone Giacopuzzi, Stefano Milleri, Anna Tomezzoli, Serena Contarelli, Maria Bencivenga, Irene Rossi, Davide Melisi
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background:Prognosis of patients affected by metastatic esophageal–gastric junction (EGJ) or gastric cancer (GC) remains dismal. Trastuzumab, an anti-HER2 monoclonal antibody, is the only targeted agent approved for the first-line treatment of pati